Cellceutix Provides Additional Insight Into Successful Phase 2 Trial for Treating PsoriasisSYS-CON Media (press release)You should not place undue reliance on any forward-looking statements. Cellceutix undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after …and more »
[monetize id=”1″]
[monetize id=”2″]
Cellceutix Phase 2 Trial of Prurisol for Mild to Moderate Psoriasis Meets Primary EndpointMarketwired (press release)Were that site to have been excluded from overall data analysis, as is done in some clinical studies (refer to the journal article linked to below, published findings from another psoriasis study), 43.7% of patients in the 200mg Prurisol arm would have …and more »